Ultragenyx Pharmaceutical Inc. Earnings

Ultragenyx Pharmaceutical Inc.’s revenue jumped 27.99% since last year same period to $139.29Mn in the Q1 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -15.52% fall in its revenue since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit jumped 11.49% since last year same period to $-151.08Mn in the Q1 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -13.27% fall in its net profits since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit margin jumped 30.84% since last year same period to -108.46% in the Q1 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -34.07% fall in its net profit margins since last 3-months.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.29 - a -0.78% fall from last quarter’s estimates.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at -1.29.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Ultragenyx Pharmaceutical Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.